ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by CARMA FUND and RV Invest, with participation from MP Beteiligungs GmbH, Hessen Kapital I, Bruker Invest, and High-Tech Gründerfonds.
Akribion’s core technology leverages G-dase® E nucleases, a novel class of enzymes that selectively eliminate target cells by degrading their DNA and RNA. This targeted cell depletion approach offers a promising avenue for developing innovative cancer therapies and treatments for other diseases. G-dase® E nucleases are designed to be highly specific, only eliminating cells that express a specific RNA sequence, thereby minimizing off-target effects and ensuring that healthy cells remain unaffected.
“Akribion is unlocking a whole new class of therapeutic possibilities with our approach,” said Lukas Linnig, Co-Founder and Co-CEO of Akribion. “Our proprietary G-dase® E nucleases allow for highly specific cell depletion based on the presence of a predetermined RNA sequence. While we are initially focused on advancing groundbreaking precision oncology therapies, we believe this technology has broad applications across various diseases, including autoimmune diseases, fibrosis, and infectious diseases.”
Dr. Martin Raditsch, General Partner at CARMA FUND, commented, “Akribion’s unique technology enables the creation of a new class of oncology therapeutics with the potential for improved patient outcomes. We are excited to partner with this exceptional team to translate this innovative science into impactful therapies.”
Dr. Aleksei Zeifman, Investment Director at RV Invest, added, “We are thrilled to support Akribion’s entrepreneurial team as they unlock the full potential of their unique technology. The high adaptability of the G-Dase® E platform makes it a perfect tool to leverage our emerging knowledge of the genomic signatures of diseases across various therapeutic areas.”
About Akribion Therapeutics
Akribion Therapeutics is a biotechnology company developing a novel platform for programmable cell depletion based on G-dase® E nucleases. This innovative technology provides a targeted approach to eliminate specific cells by selectively destroying their DNA and RNA. By designing guide RNAs that specifically recognize the RNA sequences of target cells, Akribion aims to develop therapies for a range of diseases, including cancer, autoimmune diseases, fibrosis, and infectious diseases.
Founded in 2024 and based in Zwingenberg, Germany, Akribion was spun out of BRAIN Biotech AG, a leader in biosolutions for industrial applications. The company is led by Co-Founders and Co-CEOs Dr. Michael Krohn and Lukas Linnig. Dr. Paul Scholz, the principal inventor of G-dase® E technology, has joined Akribion as Head of Research and Development.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
